Literature DB >> 27170271

Audit of compliance with the British Committee for Standards in Haematology (BCSH) revised guidelines for the diagnosis and assessment of treatment response of hairy cell leukemia in University Hospital Galway.

K Velazquez-Kennedy1, C Crowe2, B Craven2, J Walsh2, C Prendergast2, J Krawczyk2.   

Abstract

INTRODUCTION: Hairy cell leukemia (HCL) is an uncommon B cell lymphoproliferative disorder. The object of the present audit was to assess whether the investigation and management of HCL in University College Hospital Galway (UCHG) complies with the British Committee for Standards in Haematology (BCSH) guidelines.
METHODS: Following a review of the records in our Haematology Department, 18 cases of HCL were identified between January 2006 and October 2014.
RESULTS: Blood film examination had been performed in all cases. Flow cytometry of liquid material had been undertaken in 89 % (n = 16) of cases, of which only 31 % (n = 5) included all four hairy cell panel markers (CD11c, CD25, CD103, CD123). Although all initial trephine biopsies included CD20, none analyzed DBA44. Only 65 % (n = 11) of treated patients had a post-treatment bone marrow biopsy preformed.
CONCLUSION: This audit highlights areas of improvement in the diagnosis and management of HCL in UCHG, which do not currently adhere to the BCSH recommendations.

Entities:  

Keywords:  Hairy cell leukemia; Hairy cell leukemia assessment of treatment response; Hairy cell leukemia diagnosis and management; Hairy cell leukemia guidelines; Hairy cell panel markers; University Hospital Galway

Mesh:

Year:  2016        PMID: 27170271     DOI: 10.1007/s11845-016-1460-4

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  7 in total

1.  Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*.

Authors:  Gail Jones; Nilima Parry-Jones; Bridget Wilkins; Monica Else; Daniel Catovsky
Journal:  Br J Haematol       Date:  2011-11-24       Impact factor: 6.998

2.  Eradication of minimal residual disease in hairy cell leukemia.

Authors:  Farhad Ravandi; Jeffrey L Jorgensen; Susan M O'Brien; Srdan Verstovsek; Charles A Koller; Stefan Faderl; Francis J Giles; Alessandra Ferrajoli; William G Wierda; Shirley Odinga; Xuelin Huang; Deborah A Thomas; Emil J Freireich; Dan Jones; Michael J Keating; Hagop M Kantarjian
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

3.  Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.

Authors:  A Saven; C Burian; J A Koziol; L D Piro
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

Review 4.  How I treat hairy cell leukemia.

Authors:  Michael R Grever
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

5.  Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.

Authors:  Paulette Mhawech-Fauceglia; Martin Oberholzer; Senait Aschenafi; Audrey Baur; Michael Kurrer; Albert Von Rohr; Shu-Fang Hsu-Schmitz; Beatrice Wagner; Francoise Delacretaz; Nina Hurwitz
Journal:  Arch Pathol Lab Med       Date:  2006-03       Impact factor: 5.534

6.  Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.

Authors:  F Maloisel; L Benboubker; M Gardembas; B Coiffier; M Divine; C Sebban; M Blanc; J-F Abgrall; P Lederlin; J-L Harousseau; A-M Blaise; B Grosbois; P Morice; C Ghandour; S Castaigne
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

Review 7.  Long-term follow-up after purine analogue therapy in hairy cell leukaemia.

Authors:  Monica Else; Claire E Dearden; Daniel Catovsky
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.